|Day Low/High||100.40 / 101.19|
|52 Wk Low/High||58.59 / 100.96|
The fundamentals are there, supported by earnings. Let's look at the charts.
It depends on which aisle of the stock market you're on.
LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.
The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.
The ECB's super dovish message was good for the markets.
Shares of DowDuPont jumped after issuing preliminary third-quarter results.
An observation: Despite being within 1% of the all-time high in the S&P Index, this week's feature was a number of investment potholes --relatively large sized individual fundamental disappointments followed by marked stock price drops. Celgene , B...
What was dangerous is now safe, what was safe is now risky.
A frequent theme of mine is the lack of follow-up and accountability by commentators and "talking heads" in the media of the many ideas that have soured. Losers are part of the game -- and those who don't confess to mistakes are either lying or, as...
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't advise panicking over Celgene.
Breadth is positive, but pockets of momentum are very limited.
This morning I added to Allergan on weakness in biotech -- a true contrarian and counterintuitive bet considering the struggles of Celgene et al. However, I am still only medium in size in my AGN position.
The Summit, N.J.-based firm on Oct. 26 unveiled third-quarter results and updated its 2017 outlook and financial targets for 2020.
As an observation, I find -- and this is characteristic of a mature bull market -- that many investors, strategists, commentators and talking heads are just taking shots in the dark on stocks these days and are not adjusting their outlooks for chang...
Celgene is down around $13 in premarket trading after disappointment over its third-quarter results. This stock has been widely heralded on "Fast Money" and elsewhere, mostly on technical grounds. But I must say, our Bobby Lang showed a lot of ...
The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.
With thirty minutes to go: * Watching CNBC and the rest of the business media, one would conclude that "everyone is in the pool." It is, as one talking head just declared..."a buy/buy scenario." (Enough said/written). * The bond market's decline was...
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
Look at this recent pullback as an opportunity for a buy-side entry.
You have options when trading options, so don't give up your leverage or advantage too soon.
"While options can give market participants the protection they are intended to provide, they can also increase the degree of a counter move, once it gets going, as those who wrote the protection scramble to unwind their own exposure." -- Kass Diary...
Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."